Bioxytran Secures Commercial Distribution Agreement for A-SUQAR® Dietary Supplement
BIXT sits 42% above its 52-week low of $0.034 on light trading volume (0.3× avg).
Summary
Bioxytran signed a distribution agreement with Khoury Medical LTD for its A-SUQAR® dietary supplement, marking its entry into commercial revenue generation and validating its core technology platform.
Key Events · M&A and Partnerships · BIXT
-
Distribution Agreement Signed
Bioxytran entered into a commercial Distribution Agreement with Khoury Medical LTD for its A-SUQAR® chewable dietary supplement.
-
Commercialization of A-SUQAR®
Khoury Medical will commercialize A-SUQAR®, a proprietary partially hydrolyzed guar gum (PHGG) formulation, intended to support healthy post-meal blood sugar levels.
-
Strategic Shift to Commercial Revenue
The agreement represents an important milestone for Bioxytran, transitioning it to a company with potential recurring commercial revenue and providing market validation for its technology platform.
-
Preserves Pharmaceutical Focus
The agreement is specifically for non-pharmaceutical dietary products, allowing Bioxytran to independently advance its pharmaceutical and antiviral development programs.
Analysis · BIXT · Life Sciences
Bioxytran, a micro-cap biotechnology company, has entered into a commercial distribution agreement with Khoury Medical LTD for its A-SUQAR® dietary supplement. This agreement marks a strategic shift for Bioxytran, moving it from a purely development-stage organization to one with a pathway to recurring commercial revenue. While A-SUQAR® is a nutraceutical product, it provides crucial market validation for the company's proprietary carbohydrate-based galectin platform, which also underpins its higher-value pharmaceutical and antiviral programs, including the recently successful ProLectin-M Phase 2 trial. The deal is structured to maintain a capital-efficient commercial model for Bioxytran, allowing it to focus on its core intellectual property and pharmaceutical development.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.1% of the 1612 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIXT was trading at $0.05 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.8M. The 52-week trading range was $0.03 to $0.23. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.